Keywords
Dementia
Alzheimer's Diseases
Therapeutic measures
Biomarkers
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the role of neuroinflammation in dementia, aiming to identify therapeutic targets for treatment and prevention. Bibliographic review: Neuroinflammation is central to the progression of dementias, such as Alzheimer's disease (AD) and cognitive vascular dementia (VCID), mediated by the activation of glial cells that release pro-inflammatory and neurotoxic cytokines, promoting neurodegeneration. Investigation of glial cells reveals their crucial role in the immune response and maintenance of brain homeostasis, highlighting the importance of balancing pro- and anti-inflammatory cytokines in modulating neuroinflammation. Advances in diagnosis and treatment, including biomarkers such as translocator protein (TSPO) and targeted therapeutic strategies, show promise in mitigating the effects of neuroinflammation. Final considerations: Neuroinflammation is crucial in the progression of dementia, acting synergistically with other pathological mechanisms and accelerating neurodegeneration. Evidence points to the modulation of inflammation as a promising therapeutic strategy. However, complexity requires personalized approaches, with an emphasis on identifying specific biomarkers and phenotypes. Future research focused on these areas may offer new directions for more effective interventions, transforming dementia management.
References
AL-GHRAIYBAH NF, et al. Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease. International Journal of Molecular Sciences, 2022; 23: 10572.
ANGIULLI F, et al. Blood-Based Biomarkers of Neuroinflammation in Alzheimer’s Disease: A Central Role for Periphery? Diagnostics, 2021; 11: 1525.
ATRI A. Current and Future Treatments in Alzheimer's Disease. Seminars in Neurology, 2019; 39(2): e240.
BRADBURN S, et al. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease. Ageing Research Reviews, 2019; 50: 1008.
CERQUEIRA SR, et al. Neuroinflammation Treatment via Targeted Delivery of Nanoparticles. Frontiers in Cellular Neuroscience, 2020; 14: 576037.
CHOI S-B, et al. The Molecular Mechanisms of Neuroinflammation in Alzheimer’s Disease. International Journal of Molecular Sciences, 2023; 24: 11757.
DONNELLY CR, et al. Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain. Neurotherapeutics, 2020; 8929.
EO DY, et al. Exercise and Neuroinflammation in Health and Disease. Int Neurourol J, 2019; 30.
GUZMAN-MARTINEZ L, et al. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Frontiers in Neurology, 2023; 4: 167.
HAMPEL H, et al. Precision medicine - the golden gate for detection, treatment, and prevention of Alzheimer’s Disease. J Prev Alzheimer’s Dis, 2016; 3: 243–59.
JUNG YJ, et al. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Front. Cell Dev. Biol, 2019; 7: 313.
KIM J, et al. Neuroimaging Modalities in Alzheimer’s Disease Diagnosis. J. Neuroimaging, 2022; 32(4): 593-605.
KONSMAN, JP. Cytokines in the Brain and Neuroinflammation: We Didn’t Know. Pharmaceuticals, 2022; 15: 140.
KREISL WC, et al. Pet Imaging of Neuroinflammation in Neurological Disorders. J Nucl Med, 2020; 63(5): 745-756.
LARREA A, et al. Neuroinflammation in the Evolution of Motor Function in... Curr. Issues Mol. Biol. 2023; 45: 8583.
LENG F e EDISON P. Neuroinflammation and microglial activation in Alzheimer disease. Neuroimaging Clinics, 2020; 30(2): 17-24.
LUC M, et al. Neuroinflammation in Dementia—Therapeutic Directions in a COVID-19 Pandemic Setting. J. Neuroimmune Pharmacol, 2022; 17(3): 412-423.
MASDEU JC, et al. Imaging Neuroinflammation in Neurodegenerative Disorders. J Nucl Med, 2022; 63: 45-52.
MEYER, et al. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry, 2020; 7(12): 1064-1074.
MOTTA C, et al. Protective Role of Cerebrospinal Fluid against Cortical Spreading Depression. Experimental Neurology, 2020; 324: 113112.
MOZAFARI N, et al. Targeted drug delivery systems to control neuroinflammation in central nervous system disorders. J. Controlled Release, 2021; 329: 1-18.
SAHA S, et al. A Perspective on Nrf2 Signaling. Int. J. Mol. Sci, 2022; 23: 10572.
TAIPA R, et al. Proinflammatory and Anti-inflammatory Cytokines in the CSF of Dementia Patients. Neurobiology of Aging, 2019; 76: 125-132.
TIAN Z, et al. Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence and Future Directions. J. Neuroinflamm. 2023; 10: 160.
VANDENBARK AA, et al. Microglia and Astrocyte Involvement in Neurodegeneration and Brain Cancer. Front. Cell. Neurosci, 2023; 17: 10248.
VOET S, et al. Inflammasomes in Neuroinflammatory and Neurodegenerative Diseases. EMBO Mol Med, 2019; 11: 10248.
XU S, et al. Glial Cells' Role in the Immune Response in Ischemic Stroke. J. Neuroinflamm. 2020; 11: 294.
YILMAZ C, et al. Neurosteroids as Regulators of Neuroinflammation. Front. Neuroendocrinol. 2019; 55: 100788.
ZHU X, et al. Neuroinflammation Induction and Alteration of Hippocampal Neurogenesis. Int. J. Neuropsychopharmacol. 2020; 24(5): 419-433.